Tempest Therapeutics, Inc. reported significant financial changes in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $3.5 million for the quarter, a 67% decrease from the $10.6 million loss reported in the same period last year. For the nine months ending September 30, 2025, the net loss was $22.2 million, down from $28 million in the prior year. The reduction in losses is attributed to a substantial decrease in research and development expenses, which fell by 92% to $570,000 for the quarter, compared to $7.6 million in the previous year. This decline reflects the company's strategic decision to prioritize its resources while exploring alternatives to maximize shareholder value.
In terms of liquidity, Tempest's cash and cash equivalents decreased to $7.5 million as of September 30, 2025, down from $30.3 million at the end of 2024. The company has been actively managing its cash flow, resulting in a cash used in operating activities of $23.2 million for the nine months ended September 30, 2025, slightly higher than the $22.9 million used in the same period last year. The company has also reduced its workforce by 21 employees as part of its cost-cutting measures, which became effective on April 30, 2025.
Strategically, Tempest is focusing on its lead product candidate, amezalpat, which is set to enter a pivotal Phase 3 study for first-line liver cancer. The company received positive feedback from the FDA regarding the trial design and has also secured Orphan Drug Designation for amezalpat. Additionally, the company is preparing to initiate a Phase 2 study for its second candidate, TPST-1495, in patients with Familial Adenomatous Polyposis, although this is subject to potential delays due to the ongoing U.S. government shutdown.
The company has also engaged MTS Health Partners, L.P. to assist in exploring strategic alternatives, including potential mergers, acquisitions, or partnerships. However, the filing indicates substantial doubt about the company's ability to continue as a going concern for the next 12 months, given its current cash position and ongoing operating losses. Tempest's management has not set a timetable for the completion of its strategic review, emphasizing the need for additional funding to support its operations moving forward.
About Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc. is a clinical-stage biotech company developing targeted and immune-mediated cancer therapies. Its pipeline includes first-in-class oral small molecules like amezalpat for hepatocellular carcinoma and TPST-1495 targeting prostaglandin receptors. The company focuses on innovative oncology treatments, leveraging scientific research, strategic collaborations, and patent protection to address unmet medical needs in cancer markets worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.